Why the study?
Does aggressive lipid-lowering therapy reduce coronary heart disease morbidity and mortality in patients with or at risk for CHD?
Does aggressive lipid-lowering therapy reduce coronary heart disease morbidity and mortality in patients with or at risk for CHD?
Aggressive lipid-lowering therapy, including combination therapy and newer statins, is necessary to achieve updated NCEP ATP III guideline targets for LDL-C and HDL-C in patients at risk for CHD.
Answers are grounded in this paper and cite their sources.
Supports aggressive lipid-lowering to meet LDL-C/HDL-C targets; leaves open prospective validation of outcome benefits.
Recent primary and secondary intervention studies have shown that reduction of low-density lipoprotein cholesterol (LDL-C) with statins significantly reduced coronary heart disease (CHD) morbidity and mortality. However, many patients with dyslipidemia who have or are at risk for CHD do not reach target LDL-C goals. The recently updated National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines identify a group of patients at very high risk for CHD for more aggressive LDL-C reduction and reaffirm the importance of high-density lipoprotein cholesterol (HDL-C) by raising the categorical threshold to 40 mg/dl. Lipid-lowering therapy needs to be more aggressive in both primary and secondary prevention settings, and therapy should be considered to increase HDL-C as well as lower LDL-C in order to improve patient outcomes. Both combination therapy and the next generation of statins may provide improved efficacy across the dyslipidemia spectrum.
No takes yet. Share an insight, caveat, or question.
Daniel J. Rader (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: